Fudan-Zhangjiang
FDZJ concentrates on the business of R & D, manufacturing, and sales of innovative drugs.
Fudan-Zhangjiang, founded in November, 1996 and headquartered in Shanghai, is a biopharmaceutical developer. The founder is Wang Haibo. Listed on the HKEX on December 16, 2013, the company's major shareholders are Shanghai Pharmaceuticals Holding Co., Ltd., China New Enterprise Phase II Investment Co., Ltd. and Yang Zongmeng. Rivals that have direct and indirect competition with Fudan-Zhangjiang include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
AI Pharmaceutical R&D Company DP Technology Raises New Round of Over CNY 700 Mn Financing
EqualOcean has learned that DP Technology(深势科技), an AI pharmaceutical research company, has recently successfully completed a funding round of over CNY 700 million. Investors in this round include Zhongyuan Capital(众源资本), MSA Capital(和玉资本), Loyal Valley Capital(正心谷资本), Evergreen Scitech Delta(深势科技), and many other industry-specific investors, with Lighthouse Capital(光源资本) serving as the exclusive financial advisor.
Aug 22, 2023 03:34 PM